The journey of canakinumab; on- and off-label indications

  • Daniela Marotto Rheumatology Unit, P. Dettori Hospital, Tempio Pausania (SS), Italy.
  • Alberto Batticciotto Rheumatology Unit, Internal Medicine Department, ASST Settelaghi, Ospedale di Circolo - Fondazione Macchi, Varese, Italy.
  • Angela Ceribelli Rheumatology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy.
  • Piercarlo Sarzi Puttini | Rheumatology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy.


The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarize the on- and off-label use of canakinumab (ILARIS®).


Download data is not yet available.


PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

IL-1β, inflammation, interleukin 1, rheumatic disease, IL-1 inhibitors, auto-inflammatory disease, CAPS, TRAPS, biological therapies, familial Mediterranean fever, adult-onset Still disease, SJIA, HIDS, pregnancy.
  • Abstract views: 365

  • PDF: 217
  • HTML: 106
How to Cite
Marotto, D., Batticciotto, A., Ceribelli, A., & Sarzi Puttini, P. (2019). The journey of canakinumab; on- and off-label indications. Beyond Rheumatology, 1(1), 22-30.

Most read articles by the same author(s)